Could new US investment curbs complicate China’s biotech licensing surge?

The US Treasury Department has proposed new rules that could limit Chinese biotech firms' access to direct US investment or joint ventures. This move may complicate China's recent surge in biotech licensing agreements, as Chinese companies rely on foreign investment to fund their global expansion. The proposed rules could disrupt deal structures, making it harder for Chinese biotech firms to secure funding and partnerships. This could have significant implications for the global biotech industry, particularly if Chinese companies are forced to seek alternative funding sources.

Why it matters

The proposed US investment curbs could limit Chinese biotech firms' ability to expand globally. This could disrupt deal structures and create uncertainty for investors.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to South China Morning Post. For information only — not financial advice.